Your browser doesn't support javascript.
loading
Guidelines and definitions for research on epithelial-mesenchymal transition.
Yang, Jing; Antin, Parker; Berx, Geert; Blanpain, Cédric; Brabletz, Thomas; Bronner, Marianne; Campbell, Kyra; Cano, Amparo; Casanova, Jordi; Christofori, Gerhard; Dedhar, Shoukat; Derynck, Rik; Ford, Heide L; Fuxe, Jonas; García de Herreros, Antonio; Goodall, Gregory J; Hadjantonakis, Anna-Katerina; Huang, Ruby Y J; Kalcheim, Chaya; Kalluri, Raghu; Kang, Yibin; Khew-Goodall, Yeesim; Levine, Herbert; Liu, Jinsong; Longmore, Gregory D; Mani, Sendurai A; Massagué, Joan; Mayor, Roberto; McClay, David; Mostov, Keith E; Newgreen, Donald F; Nieto, M Angela; Puisieux, Alain; Runyan, Raymond; Savagner, Pierre; Stanger, Ben; Stemmler, Marc P; Takahashi, Yoshiko; Takeichi, Masatoshi; Theveneau, Eric; Thiery, Jean Paul; Thompson, Erik W; Weinberg, Robert A; Williams, Elizabeth D; Xing, Jianhua; Zhou, Binhua P; Sheng, Guojun.
Affiliation
  • Yang J; Departments of Pharmacology and Pediatrics, Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. jingyang@ucsd.edu.
  • Antin P; Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
  • Berx G; Molecular and Cellular Oncology Lab, Department of Biomedical Molecular Biology, Ghent University, Cancer Research Institute Ghent (CRIG), VIB Center for Inflammation Research, Ghent, Belgium.
  • Blanpain C; Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
  • Brabletz T; Department of Experimental Medicine 1, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Bronner M; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Campbell K; Department of Biomedical Science and Bateson Centre, University of Sheffield, Sheffield, UK.
  • Cano A; Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas 'Alberto Sols' (CSIC-UAM), IdiPAZ & Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Casanova J; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology/Institut de Biologia Molecular de Barcelona (IBMB-CSIC), Barcelona, Spain.
  • Christofori G; Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Dedhar S; Department of Biochemistry and Molecular Biology, University of British Columbia and British Columbia Cancer Research Centre, Vancouver, BC, Canada.
  • Derynck R; Departments of Cell and Tissue Biology, and Anatomy, University of California at San Francisco, San Francisco, CA, USA.
  • Ford HL; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Fuxe J; Department of Laboratory Medicine (LABMED), Division of Pathology, Karolinska University Hospital and Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden.
  • García de Herreros A; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) and Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain.
  • Goodall GJ; Centre for Cancer Biology, An alliance of SA Pathology and University of South Australia, Adelaide, SA, Australia.
  • Hadjantonakis AK; Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Huang RYJ; School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Kalcheim C; Department of Medical Neurobiology, Institute for medical Research Israel-Canada and the Safra Center for Neurosciences, Hebrew University of Jerusalem, Hadassah Medical School, Jerusalem, Israel.
  • Kalluri R; Department of Cancer Biology, Metastasis Research Center, MD Anderson Cancer Center, Houston, TX, USA.
  • Kang Y; Department of Molecular Biology, Princeton University, Princeton, NJ, USA.
  • Khew-Goodall Y; Centre for Cancer Biology, an Alliance of SA Pathology and the University of South Australia, Adelaide, SA, Australia.
  • Levine H; Department of Physics, Northeastern University, Boston, MA, USA.
  • Liu J; Department of Anatomic Pathology, The Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Longmore GD; Department of Medicine (Oncology) and Department of Cell Biology and Physiology, ICCE Institute, Washington University, St. Louis, MO, USA.
  • Mani SA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Massagué J; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mayor R; Department of Cell and Developmental Biology, University College London, London, UK.
  • McClay D; Department of Biology, Duke University, Durham, NC, USA.
  • Mostov KE; Departments of Anatomy and Biochemistry/Biophysics, University of California, San Francisco, School of Medicine, San Francisco, CA, USA.
  • Newgreen DF; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC, Australia.
  • Nieto MA; Instituto de Neurociencias (CSIC-UMH) Avda Ramon y Cajal s/n, Sant Joan d´Alacant, Spain.
  • Puisieux A; Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France.
  • Runyan R; Institut Curie, PSL Research University, Paris, France.
  • Savagner P; Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
  • Stanger B; INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
  • Stemmler MP; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Takahashi Y; Department of Experimental Medicine 1, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
  • Takeichi M; Department of Zoology, Graduate School of Science, Kyoto University, Kyoto, Japan.
  • Theveneau E; RIKEN Center for Biosystems Dynamics Research, Kobe, Japan.
  • Thiery JP; Centre de Biologie du Développement (CBD), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, UPS, Toulouse, France.
  • Thompson EW; Guangzhou Regenerative Medicine and Health, Guangdong Laboratory, Guangzhou, China.
  • Weinberg RA; School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Williams ED; Whitehead Institute for Biomedical Research, Department of Biology, MIT Ludwig Center for Molecular Oncology, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Xing J; Australian Prostate Cancer Research Centre-Queensland (APCRC-Q) and Queensland Bladder Cancer Initiative (QBCI), School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland University of Technology, Woolloongabba, QLD, Australia.
  • Zhou BP; Department of Computational and Systems Biology and UPMC-Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Sheng G; Department of Molecular and Cellular Biochemistry and UK Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USA.
Nat Rev Mol Cell Biol ; 21(6): 341-352, 2020 06.
Article in En | MEDLINE | ID: mdl-32300252
ABSTRACT
Epithelial-mesenchymal transition (EMT) encompasses dynamic changes in cellular organization from epithelial to mesenchymal phenotypes, which leads to functional changes in cell migration and invasion. EMT occurs in a diverse range of physiological and pathological conditions and is driven by a conserved set of inducing signals, transcriptional regulators and downstream effectors. With over 5,700 publications indexed by Web of Science in 2019 alone, research on EMT is expanding rapidly. This growing interest warrants the need for a consensus among researchers when referring to and undertaking research on EMT. This Consensus Statement, mediated by 'the EMT International Association' (TEMTIA), is the outcome of a 2-year-long discussion among EMT researchers and aims to both clarify the nomenclature and provide definitions and guidelines for EMT research in future publications. We trust that these guidelines will help to reduce misunderstanding and misinterpretation of research data generated in various experimental models and to promote cross-disciplinary collaboration to identify and address key open questions in this research field. While recognizing the importance of maintaining diversity in experimental approaches and conceptual frameworks, we emphasize that lasting contributions of EMT research to increasing our understanding of developmental processes and combatting cancer and other diseases depend on the adoption of a unified terminology to describe EMT.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomedical Research / Epithelial-Mesenchymal Transition Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Animals / Humans Language: En Journal: Nat Rev Mol Cell Biol Journal subject: BIOLOGIA MOLECULAR Year: 2020 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Biomedical Research / Epithelial-Mesenchymal Transition Type of study: Guideline / Prognostic_studies / Qualitative_research Limits: Animals / Humans Language: En Journal: Nat Rev Mol Cell Biol Journal subject: BIOLOGIA MOLECULAR Year: 2020 Document type: Article Affiliation country: United States